Reports
Advanced Therapy Medicinal Products Market Size, Report 2026-2034
REPORT DETAILS
Report Code:
PM4326
No. of Pages:
116
Format:
PDF
Published Date:
Base Year:
2025
Author:
Shreyas Shirsat
Historical Data:
2021 – 2024
REPORT DETAILS
Report Code:
PM4326
Published Date:
No. of Pages:
116
Historical Data:
2021 – 2024
Format:
PDF
Author:
Shreyas Shirsat
Base Year:
2025
ABOUT THIS REPORT
Advanced Therapy Medicinal Products CDMO Market Share, Size, Trends, Industry Analysis Report, By Product (Gene Therapy, Cell Therapy, Tissue Engineered, Others); By Phase; By Indication; By Region; Segment Forecast, 2026 - 2034
What is the Current Market Size?
Advanced therapy medicinal products CDMO Market size was valued at USD 7.79 billion in 2025. The market is anticipated to grow from USD 9.19 billion in 2026 to USD 38.16 billion by 2034, exhibiting the CAGR of 19.50% during the forecast period.
Market Statistics
- 2025 Market Size: USD 7.79 billion
- 2034 Projected Market Size: USD 38.16 billion
- CAGR (2026-2034): 19.50%
- North America: Largest market in 2025
Market Overview
The advanced therapy medicinal products contract development and manufacturing organizations (ATMP CDMO) are witnessing huge demand in the marketplace, which is highly attributable to the rising pharmaceutical studies on developing new therapies with the utilization of tissue engineering, gene therapy, and gene therapeutics. Nowadays, cell and gene therapies are widely employed in the healthcare industry, primarily to treat diseases like cancer, autoimmune diseases, and neurological and genetic disorders. This is enabling the demand for CDMOs in the market.
For instance, in January 2023, Charles River and Rznomicare entered a viral vector CDMO partnership. This is to utilize collaborative power in the clinical development of RNA-based anti-cancer gene therapy in liver cancer patients.
Moreover, the prevalence of viral infections in society is emphasizing researchers to explore alternative methods, including generative medicine, with a view to developing cures for existing diseases and countering viral infections.
To Understand More About this Research: Download Sample Report
However, the stringent regulations, higher qualitative checks, and constant need for the adoption of advanced technological infrastructure, which can cost a huge amount, are expected to impede market growth.
Growth Drivers
The Rising Cell and Gene-Based Therapies in Biotechnology
Based on the advanced therapy medicinal products CDMO market analysis, one of the major driver of market growth is growing research studies on gene and cell therapies. According to the report published by the American Society of Gene+Cell Therapy Q3 2023, the gene therapies, including genetically modified therapies, which are in the developing stage, are 2,082, while RNA therapies and non-genetically modified cell therapies constitute 25% and 22%, respectively. These ongoing development activities will require advanced infrastructure to develop and manufacture therapies. This is where the need for CDMO is prominent.
The Higher Production Capability of CDMOs
In the development of cell and gene therapies, specialization in manufacturing teams is vital. The presence of experienced professionals in contract development organizations, along with the higher production capacity and availability of advanced infrastructure, is grabbing attention from biopharmaceutical companies. The growing approvals for the numerous therapies in the marketplace are expected to promote new opportunities for advanced therapeutic medicinal products and market growth.
Restraining Factors
The Talent Shortage Pertaining to Atmp Production is Likely to Impede Market Growth
Based on the ATMP CDMO market analysis, one of the major factors negatively affecting market growth is the lack of proficient people in the manufacturing of cell and gene therapies. As cell and gene therapies are in an emerging stage, the demand is outstripping the supply in the marketplace, which is making it difficult for CDMOs to hire quality staff. However, rising young professionals' interest in building a career in the biopharmaceutical space is expected to have a significant impact on the market in the coming years.
Technological & Operational Differentiators
|
Company |
Innovation |
Key Stats/Details |
|
Lonza |
TheraPEAK AmpliCell Cytokines & 293-GT Medium; Cocoon platform; Design2Optimize digital twin |
Cytokines boost immune cell expansion; AAV production; point-of-care automation (10-day vein-to-vein); in-silico process modeling for right-first-time |
|
Catalent |
Harmans gene therapy campus expansion (USD 230M+); 18 CGMP viral vector suites |
2,000L bioreactors; single-use systems for AAV scale-up; flexible multi-room suites from cell bank to drug substance |
|
Thermo Fisher |
CTS Rotea Counterflow Centrifugation; DynaCellect Magnetic Separation; closed modular workflow |
>95% cell recovery; grade C cleanroom processing; decouples processes for scalability/cost reduction |
|
Kite Pharma (Gilead) |
Yescarta optimized manufacturing; KITE DuoCore bicistronic CAR-T; KITE-753 fitness process |
5-day production (from 7); 14-day median turnaround; dual CD19/CD20 targeting + CD28/4-1BB co-stimulation |
|
Samsung Biologics |
Cell/gene therapy platforms; Plant 5 (180kL by 2025) |
End-to-end CGMP; total 784kL capacity; ADC/mRNA/multispecifics support |
Report Segmentation
The market is primarily segmented based on product, phase, indication, and region.
|
By Product |
By Phase |
By Indication |
By Region |
|
|
|
|
To Understand the Scope of this Report: Request Customization
By Product Analysis
Gene Therapy Segment is Expected to Witness the Highest Growth During the Forecast Period
The gene therapy segment is projected to grow at a CAGR during the projected period, mainly driven by the rising clinical trials of gene therapies. The total number of global gene therapies in various development stages from Q3 2022 to Q3 2023 has grown significantly with 2,031 and 2,082, respectively. These ongoing clinical trials are expected to folster the demand for ATMP CDMO.
In the advanced therapy medicinal products CDMO market forecast, the cell therapy segment led the industry market with a substantial revenue share in 2023. This is highly influenced by the rising approvals of cell therapies in the marketplace.
By Phase Analysis
Phase I Segment Accounted for the Largest Market Share in 2025
The phase I segment accounted for the largest market share in 2025. This usually includes early trials among volunteers. The increasing new developments in generative medicine are highly driving the demand for CDMOs. The number of participants in phase I clinical trials witnessed growth from 240 in Q2 to 256 in Q3 in 2023.
The phase II segment is expected to grow at the fastest rate over the next few years on account of the increased investment in the development process of therapies by biopharmaceutical companies. Normally, the therapies that pass the phase I trial will reach the next stage, which is phase II. It is the initial efficiency trial among the limited number of patients. The success of the therapy in earlier stages is enabling companies to invest higher funds in the second stage, contributing to the significant adoption of CDMO.
By Indication Analysis
Oncology Segment Held the Significant Market Revenue Share in 2025
The oncology segment held a significant market share in revenue in 2025, which was highly accelerated due to the continuous rise in research studies focusing on cancer. According to the Gene, Cell, & RNA Therapy Landscape Report Q3 2023, oncology & rare diseases are the most focused therapy areas in pre-clinical to the pre-registration and phase I to pre-registration.
Cardiology segment is expected to witness a lucrative share during the forecast period, attributable to the rising penetration of health issues related to cardiology among the global population. This is emphasizing the importance of developing therapies to address cardiology among researchers, fueling the adoption of CDMOs in the marketplace
Regional Insights
North America Region Registered the Largest Share of the Global Market in 2025
The North America has the largest market share in 2025 and is expected to continue its dominance over the study period. Region’s growth is attributed to the advancements in biotechnology. Based on the Advanced Therapy Medicinal Products CDMO market trends in the region, the U.S. registered the dominant share with the presence of robust infrastructure and rising acceptance of gene therapies. For instance, in December 2023, the U.S. Food and Drug Administration announced approval for CRISPR gene-editing therapy for sickle cell disease, Casgevy. This is expected to cumulatively drive the revenue of CDMOs in the region to meet supply targets.
The Asia Pacific region is expected to be grow at high CAGR during the projected period, owing to the growing concerns about incurable health problems among the population. The existence of a larger population in the region is encouraging institutes to invest in gene and cell therapies. For instance, in June 2023, Laurus Labs announced the investment of INR 80 crore in ImmunoACT, a Mumbai-based cell and gene therapy firm. This continuing progress in the pharmaceutical space is expected to contribute to the growth of the CDMO market for advanced therapy medicinal products during the study period.
Key Market Players & Competitive Insights
Strategic Investments to Drive the Competition
The advanced therapy medicinal products CDMO market is a mix of fragmentation and consolidation, with the presence of several players. The rising expansion activities, including mergers, acquisitions, partnerships, and strategic investments in the market, are playing a significant role in propelling the competition among major players. For instance, in June 2023, CDMO Biovian unveiled its plan to invest over €50 million to expand the Finland drug manufacturing facility.
Some of the major players operating in the global market include:
- AGC Biologics (Switzerland)
- Bio Elpida (France)
- BlueReg (France)
- Catalent (US)
- Celonic (Switzerland)
- CGT Catapult (UK)
- Lonza (Switzerland)
- Medicine Patheon (US)
- Minaris Regenerative (US)
- Rentschler Biopharma SE (US)
- WuXi Advanced Therapies (US)
Recent Developments in the Industry
- December 2025: Nona Biosciences and Porton CDMO collaborated on the end-to-end R&D and manufacturing of complex antibody therapies, including bispecifics. The alliance aims to accelerate development timelines and overcome industry challenges related to process development, regulatory hurdles, and commercialization.
- November 2023: the European government established the Advanced Therapy Medicinal Products Working Group to regulate gene therapies, cell therapies, and tissue engineering products.
- July 2023: Korro Bio and Frequency Therapeutics entered into a merger agreement to focus on the advancement of RNA editing programmes as well as to promote Alpha-1 antitrypsin deficiency candidates into trials.
Report Coverage
The advanced therapy medicinal products CDMO market report emphasizes on key regions across the globe to provide better understanding of the product to the users. Also, the report provides market insights into recent developments, trends and analyzes the technologies that are gaining traction around the globe. Furthermore, the report covers in-depth qualitative analysis pertaining to various paradigm shifts associated with the transformation of these solutions.
The report provides detailed analysis of the market while focusing on various key aspects such as competitive analysis, product, phase, indication and their futuristic growth opportunities.
Advanced Therapy Medicinal Products CDMO Market Report Scope
|
Report Attributes |
Details |
|
Market size value in 2025 |
USD 7.79 billion |
| Market size value in 2026 | USD 9.19 billion |
|
Revenue forecast in 2034 |
USD 38.16 billion |
|
CAGR |
19.50% from 2026 – 2034 |
|
Base year |
2025 |
|
Historical data |
2021 – 2024 |
|
Forecast period |
2026 – 2034 |
|
Quantitative units |
Revenue in USD billion and CAGR from 2026 to 2034 |
|
Segments covered |
|
|
Regional scope |
|
|
Competitive Landscape |
|
|
Report Format |
|
|
Customization |
Report customization as per your requirements with respect to countries, region, and segmentation. |
FAQ's
key companies in Advanced Therapy Medicinal Products CDMO Market are AGC Biologics, Bio Elpida, BlueReg, Catalent, Celonic, CGT Catapult, Lonza
Advanced therapy medicinal products CDMO Market exhibiting the CAGR of 19.50% during the forecast period.
The Advanced Therapy Medicinal Products CDMO Market report covering key segments are product, phase, indication and region.
key driving factors in Advanced Therapy Medicinal Products CDMO Market are rising cell and gene-based therapies in biotechnology
The global advanced therapy medicinal products CDMO market size is expected to reach USD 38.16 billion by 2034.
Page last updated on: Jan-2024
Download Sample Report of Advanced Therapy Medicinal Products Market
Please fill out the form to request a customized copy of the research report.
